Academic Journal
Combination chemotherapy in advanced adrenocortical carcinoma
| العنوان: | Combination chemotherapy in advanced adrenocortical carcinoma |
|---|---|
| المؤلفون: | M. Fassnacht, M. Terzolo, B. Allolio, E. Baudin, H. Haak, A. Berruti, S. Welin, C. Schade Brittinger, A. Lacroix, B. Jarzab, H. Sorbye, D. J. Torpy, V. Stepan, D. E. Schteingart, W. Arlt, M. Kroiss, S. Leboulleux, P. Sperone, A. Sundin, I. Hermsen, S. Hahner, H. S. Willenberg, A. Tabarin, M. Quinkler, C. De La Fouchardiere, M. Schlumberger, F. Mantero, D. Weismann, F. Beuschlein, H. Gelderblom, H. Wilmink, M. Sender, M. Edgerly, W. Kenn, T. Fojo, H. H. Muller, B. Skogseid, M. Haaf, S. Johanssen, A. C. Koschker, K. Laubner, S. Sbiera, J. Schiemann, S. Wortmann, M. Haase, M. Schott, M. Möhlig, K. Zopf, N. Reisch, M. Betz, M. Reincke, B. Isermann, S. Bornstein, C. Fottner, A. Bose, S. Petersenn, H. Leitolf, S. Klose, H. Wolf, C. Chougnet, J. More, M. L. Nunes, J. P. Droz, P. Nicolli, O. Chabre, A. Clergeot, F. Schillo, A. Penfornis, C. Do Cao, F. Goldwasser, P. Rodien, A. Ferrero, P. Perotti, Anna P. Cicala Mv, S. Della Casa, M. Mannelli, V. Piccini, M. W. Dercksen, J. A. Romijn, J. Ouwerkerk, J. H. Devries, B. Eriksson, E. T. Janson, D. Granberg, K. Oberg, H. Ahlman, M. Garkavij, N. Wall, U. Falkmer, G. Hammer, H. J. Olney, I. Bourdeau, L. Bourque, S. Szpak Ulczok, M. Jarzab, H. Holte, A. Fossa, F. Ploner, U. Mansmann, H. J. Schmoll, B. Simonsson, TOSCANO, Vincenzo |
| المساهمون: | M., Fassnacht, M., Terzolo, B., Allolio, E., Baudin, H., Haak, A., Berruti, S., Welin, C., Schade Brittinger, A., Lacroix, B., Jarzab, H., Sorbye, D. J., Torpy, V., Stepan, D. E., Schteingart, W., Arlt, M., Kroi, S., Leboulleux, P., Sperone, A., Sundin, I., Hermsen, S., Hahner, H. S., Willenberg, A., Tabarin, M., Quinkler, C., De La Fouchardiere, M., Schlumberger, F., Mantero, D., Weismann, F., Beuschlein, H., Gelderblom, H., Wilmink, M., Sender, M., Edgerly, W., Kenn, T., Fojo, H. H., Muller, B., Skogseid, M., Haaf, S., Johanssen, A. C., Koschker, K., Laubner, S., Sbiera, J., Schiemann, S., Wortmann, M., Haase, M., Schott, M., Möhlig, K., Zopf, N., Reisch, M., Betz, M., Reincke, B., Isermann, S., Bornstein, C., Fottner, A., Bose, S., Petersenn, H., Leitolf, S., Klose, H., Wolf, C., Chougnet, J., More, M. L., Nune, J. P., Droz, P., Nicolli, O., Chabre, A., Clergeot, F., Schillo, A., Penforni, C., Do Cao, F., Goldwasser, P., Rodien, A., Ferrero, P., Perotti, Anna P., Cicala Mv, S., Della Casa, M., Mannelli, V., Piccini, M. W., Dercksen, J. A., Romijn, J., Ouwerkerk, J. H., Devrie, B., Eriksson, E. T., Janson, D., Granberg, K., Oberg, H., Ahlman, M., Garkavij, N., Wall, U., Falkmer, G., Hammer, H. J., Olney, I., Bourdeau, L., Bourque, S., Szpak Ulczok, M., Jarzab, H., Holte, A., Fossa, F., Ploner, U., Mansmann, H. J., Schmoll |
| سنة النشر: | 2012 |
| المجموعة: | Sapienza Università di Roma: CINECA IRIS |
| الوصف: | BACKGROUND: Adrenocortical carcinoma is a rare cancer that has a poor response to cytotoxic treatment. METHODS: We randomly assigned 304 patients with advanced adrenocortical carcinoma to receive mitotane plus either a combination of etoposide (100 mg per square meter of body-surface area on days 2 to 4), doxorubicin (40 mg per square meter on day 1), and cisplatin (40 mg per square meter on days 3 and 4) (EDP) every 4 weeks or streptozocin (streptozotocin) (1 g on days 1 to 5 in cycle 1; 2 g on day 1 in subsequent cycles) every 3 weeks. Patients with disease progression received the alternative regimen as second-line therapy. The primary end point was overall survival. RESULTS: For first-line therapy, patients in the EDP-mitotane group had a significantly higher response rate than those in the streptozocin-mitotane group (23.2% vs. 9.2%, P<0.001) and longer median progression-free survival (5.0 months vs. 2.1 months; hazard ratio, 0.55; 95% confidence interval [CI], 0.43 to 0.69; P<0.001); there was no significant between-group difference in overall survival (14.8 months and 12.0 months, respectively; hazard ratio, 0.79; 95% CI, 0.61 to 1.02; P = 0.07). Among the 185 patients who received the alternative regimen as second-line therapy, the median duration of progression-free survival was 5.6 months in the EDP-mitotane group and 2.2 months in the streptozocin-mitotane group. Patients who did not receive the alternative second-line therapy had better overall survival with first-line EDP plus mitotane (17.1 month) than with streptozocin plus mitotane (4.7 months). Rates of serious adverse events did not differ significantly between treatments. CONCLUSIONS: Rates of response and progression-free survival were significantly better with EDP plus mitotane than with streptozocin plus mitotane as first-line therapy, with similar rates of toxic events, although there was no significant difference in overall survival. (Funded by the Swedish Research Council and others; FIRM-ACT ClinicalTrials.gov number, ... |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | STAMPA |
| اللغة: | English |
| Relation: | info:eu-repo/semantics/altIdentifier/pmid/22551107; info:eu-repo/semantics/altIdentifier/wos/WOS:000304863400008; volume:366; issue:23; firstpage:2189; lastpage:2197; numberofpages:9; journal:NEW ENGLAND JOURNAL OF MEDICINE; http://hdl.handle.net/11573/456050; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-84861888600; http://www.scopus.com/inward/record.url?eid=2-s2.0-84861888600&partnerID=65&md5=4fc98f0e3f7221d1ef73b2b56f0fe12d |
| DOI: | 10.1056/nejmoa1200966 |
| الاتاحة: | http://hdl.handle.net/11573/456050 https://doi.org/10.1056/nejmoa1200966 http://www.scopus.com/inward/record.url?eid=2-s2.0-84861888600&partnerID=65&md5=4fc98f0e3f7221d1ef73b2b56f0fe12d |
| رقم الانضمام: | edsbas.946742F0 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1056/nejmoa1200966 |
|---|